NEW YORK (GenomeWeb News) – Kreatech Diagnostics and Oridis Biomarkers today said that they will co-develop and commercialize DNA-FISH assays for oncology applications.

The firms intend to develop the assays as companion diagnostics for pharmaceutical firms conducting pre-clinical and clinical development of new compounds. Amsterdam, The Netherlands--based Kreatech said that it expects to begin commercializing assays in the second half of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.